8/102 sources · 2 publishersUpdated Oct 20, 19:17 UTC
Quantum BioPharma’s Unbuzzd trial shows lower BAC and improved alertness in small study
Quantum BioPharma reported that its company‑sponsored, placebo‑controlled Unbuzzd trial in 26 adults produced lower estimated blood‑alcohol concentrations and better alertness, with some participants also experiencing less severe headaches. The study’s mixed results and limited sample size were highlighted, and the company said larger, independent trials are needed to confirm the findings.
Why it matters
The company notes that additional trials are required before the formulation can be commercialized, so investors should watch for future study outcomes that could affect licensing or product launch timelines.
Key facts
- 1The trial involved 26 adult participants. tradingview.com
- 2The study was company‑sponsored and placebo‑controlled. tradingview.com
- 3Results showed lower estimated blood‑alcohol concentration and improved alertness. tradingview.com
- 4Some participants reported reduced headache severity. finance.yahoo.com
- 5The company said larger, independent trials are needed for validation. finance.yahoo.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.